These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10085497)

  • 1. Synthesis of qualitative research on drug use in the European Union: report on an EMCDDA project. European Monitoring Centre for Drugs and Drug Addiction.
    Fountain J; Griffiths P
    Eur Addict Res; 1999 Mar; 5(1):4-20. PubMed ID: 10085497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addiction research centres and the nurturing of creativity. Monitoring the European drug situation: the ongoing challenge for the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
    Griffiths P; Mounteney J; Lopez D; Zobel F; Götz W
    Addiction; 2012 Feb; 107(2):254-8. PubMed ID: 21539630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Monitoring Centre for Drugs and Drug Addiction has a vital role in the UK's ability to respond to illicit drugs and organised crime.
    Roman-Urrestarazu A; Robertson R; Yang J; McCallum A; Gray C; McKee M; Middleton J
    BMJ; 2018 Sep; 362():k4003. PubMed ID: 30257824
    [No Abstract]   [Full Text] [Related]  

  • 4. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMCDDA Best Practice Promotion in Europe: an internet based dissemination tool.
    Ferri M; Bo A
    Adicciones; 2013; 25(1):3-6. PubMed ID: 23487273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The EMCDDA/Pompidou Group treatment demand indicator protocol: a European core item set for treatment monitoring and reporting.
    Simon R; Donmall M; Hartnoll R; Kokkevi A; Ouwehand AW; Stauffacher M; Vicente J
    Eur Addict Res; 1999 Dec; 5(4):197-207. PubMed ID: 10705187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The European Monitoring Centre for Drugs and Drug Addiction publishes the European Drug Report 2013: trends and developments.
    Eurosurveillance editorial team
    Euro Surveill; 2013 May; 18(22):. PubMed ID: 23787082
    [No Abstract]   [Full Text] [Related]  

  • 8. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Not just eliminating the mosquito but draining the swamp": A critical geopolitics of Turkish Monitoring Center for Drugs and Drug Addiction and Turkey's approach to illicit drugs.
    Evered KT; Evered EÖ
    Int J Drug Policy; 2016 Jul; 33():6-14. PubMed ID: 27267659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to implementing throughcare for problematic drug users in European prisons.
    MacDonald M; Williams J; Kane D
    Int J Prison Health; 2012; 8(2):68-84. PubMed ID: 25758018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug abuse monitoring: which pharmacoepidemiological resources at the European level?
    Lapeyre-Mestre M; Dupui M
    Therapie; 2015; 70(2):147-65. PubMed ID: 25858571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug supply indicators: Pitfalls and possibilities for improvements to assist comparative analysis.
    Singleton N; Cunningham A; Groshkova T; Royuela L; Sedefov R
    Int J Drug Policy; 2018 Jun; 56():131-136. PubMed ID: 29510885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health research in the UK: a report with a European perspective.
    McCarthy M; Dyakova M; Clarke A
    J Public Health (Oxf); 2014 Jun; 36(2):325-35. PubMed ID: 23896860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations.
    Heyerdahl F; Hovda KE; Giraudon I; Yates C; Dines AM; Sedefov R; Wood DM; Dargan PI
    Clin Toxicol (Phila); 2014 Dec; 52(10):1005-12. PubMed ID: 25361166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-level governance: The way forward for European illicit drug policy?
    Chatwin C
    Int J Drug Policy; 2007 Dec; 18(6):494-502. PubMed ID: 18061875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brexit threatens the UK's ability to tackle illicit drugs and organised crime: What needs to happen now?
    Roman-Urrestarazu A; Yang J; Robertson R; McCallum A; Gray C; McKee M; Middleton J
    Health Policy; 2019 Jun; 123(6):521-525. PubMed ID: 31054860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
    Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
    Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMCDDA framework and practical guidance for naming synthetic cannabinoids.
    Pulver B; Fischmann S; Gallegos A; Christie R
    Drug Test Anal; 2023 Mar; 15(3):255-276. PubMed ID: 36346325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of use and acute toxicity associated with the use of NBOMe drugs.
    Wood DM; Sedefov R; Cunningham A; Dargan PI
    Clin Toxicol (Phila); 2015 Feb; 53(2):85-92. PubMed ID: 25658166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.